- Olaparib was superior to chemotherapy on global health status/QoL score (vs baseline) in a phase 3 trial of patients with germline BRCA mutation and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.
Why this matters
- Quality of life is crucial in patients with poor prognosis for survival.
- Multicenter randomized OlympiAD trial (n=302) comparing olaparib monotherapy (300 mg twice daily) vs single-agent chemotherapy treatment of physician's choice (capecitabine, vinorelbine, or eribulin).
- Primary outcome was mean change from baseline in the 2-item global health status/QoL score based on the patient-completed EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30-item module).
- Funding: AstraZeneca; MSD.
- Olaparib yielded a 7.5-point greater mean change from baseline in global health status/QoL score vs chemotherapy (3.9±1.2 standard deviation [SD] vs −3.6±2.2 SD; P=.0035).
- A higher proportion of olaparib-treated patients achieved best overall response of improvement in global health status/QoL (33.7% vs 13.4%).
- Olaparib-treated patients reported less deterioration (11.7% vs 20.6%).
- The only worse outcome with olaparib was nausea/vomiting symptom score (across all visits vs baseline).
- Open-label design.